Latest Breaking News On - First line treatments high risk largeb cell lymphoma - Page 1 : comparemela.com

Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.

Jasonr westinRandomized controlled studyAxicabtagene ciloleucel versus standard of careFirst line therapyPatients with high risk largeb cellZuma 23Zuma 23 studyAxicabtagene ciloleucelStandard of care largeb cell lymphomaLargeb cell lymphomaHigh risk largeb cell lymphomaFirst line treatments high risk largeb cell lymphomaZuma 7Zuma 1Zuma 12Axi cel